{"classes":[{"categories":[{"measurements":[{"comment":"NA = not estimable; could not be calculated due insufficient number participants with events","groupId":"OG000","lowerLimit":"16.53","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"}],"units":"Participants"}],"description":"PFS is defined as the time from first dose until first documentation of progression or death, whichever comes first, as assessed by an independent review committee using modified Owen's criteria","dispersionType":"95% Confidence Interval","groups":[{"description":"Zanubrutinib 160 mg orally twice daily with or without food until progressive disease or intolerable toxicity","id":"OG000","title":"Zanubrutinib"}],"paramType":"MEDIAN","populationDescription":"Efficacy Analysis Set includes participants with confirmed Waldenström's macroglobulinemia based on central pathologic review among those who received at least one dose of study drug and with a baseline IgM (or M-protein) ≥ 5 g/L","reportingStatus":"POSTED","timeFrame":"Up to approximately 1 year and 9 months","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}